The purpose of this study is to test whether a new drug regimen will reduce the chances of side effects but be just as effective as the usual treatment for HER2-positive, ER-negative and node negative breast cancer.
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment
Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the CCTG HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Archived Bulletins
Congratulations to the PR22 Team Centre hospitalier universitaire de Sherbrooke who were recognized with the Phase III Team Award for Intergroup-Led Trials at the CCTG Spring Meeting. This award is presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance.
Congratulations to Dr. Anna Spreafico from Princess Margaret Cancer Centre (UHN) who received the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting.
We are very excited to announce that Nanthini Tharahan from the Princes Margaret Clinical Trials Support Unit has received the inaugural Excellence in Clinical Trials Conduct Award at the CCTG Spring Meeting. This award is presented to an individual who exemplifies excellence in clinical trial operations or compliance at their institution.
“I would like to express my sincere thanks for the award.”
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr Kim Chi, a medical oncologist and the Chief Medical Officer of BC Cancer. The award is presented yearly at the Annual Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.